RICHMOND, Va. / Nov 03, 2023 / Business Wire / Owens & Minor, Inc. (NYSE: OMI) today reported financial results for the third quarter ended September 30, 2023.
Third Quarter Key Highlights:
“Our performance in the third quarter is another strong indication that our business strategy and execution are working, and that we are beginning to realize the benefits of the Operating Model Realignment Program. Patient Direct continues to outperform the market, demonstrating the enduring strength of our go-to-market strategies and service offerings. Our Medical Distribution division again produced mid-single digit growth and continues to win new business. While the volatility of demand and pricing for PPE appears to be diminishing, we remain cautious on the long-term trajectory. The Operating Model Realignment Program not only continued to deliver economic benefits, but also enabled us to reassess how we do business every day. We are well on our way to achieving the objectives established when we launched this initiative in the first quarter,” said Edward A. Pesicka, President & Chief Executive Officer of Owens & Minor.
Pesicka continued, “Building on the progress we made in the first half of the year, the work we’ve done in the third quarter resulted in significant cash flow, enabling us to further reduce debt and increase our financial flexibility. We continue to align our balance sheet with our corporate strategy to support further investment in high growth categories and technology.”
Financial Summary (1) |
|
|
|
|
|
|
| |
($ in millions, except per share data)
| 3Q23 |
| 3Q22 |
| YTD 2023 |
| YTD 2022 | |
|
|
|
|
|
|
|
| |
Revenue | $2,592 |
| $2,497 |
| $7,678 |
| $7,404 | |
|
|
|
|
|
|
|
| |
Operating income, GAAP | $23.8 |
| $60.2 |
| $44.5 |
| $196.4 | |
Adj. Operating Income, Non-GAAP | $84.2 |
| $83.4 |
| $193.9 |
| $301.9 | |
|
|
|
|
|
|
|
| |
Net (loss) income, GAAP | $(6.4) |
| $12.5 |
| $(59.1) |
| $80.4 | |
Adj. Net Income, Non-GAAP | $34.1 |
| $31.4 |
| $51.9 |
| $162.5 | |
|
|
|
|
|
|
|
| |
Adj. EBITDA, Non-GAAP | $134.7 |
| $127.5 |
| $356.2 |
| $413.4 | |
|
|
|
|
|
|
|
| |
Net (loss) income per common share, GAAP | $(0.08) |
| $0.16 |
| $(0.78) |
| $1.05 | |
Adj. Net Income per share, Non-GAAP | $0.44 |
| $0.41 |
| $0.67 |
| $2.13 |
(1) Reconciliations of the differences between the non-GAAP financial measures presented in this release and their most directly comparable GAAP financial measures are included in the tables below. |
Results and Business Highlights
2023 Financial Outlook
The Company narrowed its outlook for 2023; summarized below:
The Company’s outlook for 2023 contains assumptions, including current expectations regarding the impact of general economic conditions, including inflation, and the continuation of pressure on pricing and demand in our Products & Healthcare Services segment. Key assumptions supporting the Company’s 2023 financial guidance include:
Although the Company does provide guidance for adjusted EBITDA and adjusted EPS (which are non-GAAP financial measures), it is not able to forecast the most directly comparable measures calculated and presented in accordance with GAAP without unreasonable effort. Certain elements of the composition of the GAAP amounts are not predictable, making it impracticable for the Company to forecast. Such elements include, but are not limited to, restructuring and acquisition charges, which could have a significant and unpredictable impact on our GAAP results. As a result, no GAAP guidance or reconciliation of the Company’s adjusted EBITDA guidance or adjusted EPS guidance is provided. The outlook is based on certain assumptions that are subject to the risk factors discussed in the Company’s filings with the SEC.
Investor Conference Call for Third Quarter 2023 Financial Results
Owens & Minor executives will host a conference call for investors and analysts at 8:00 a.m. ET on the same day. Participants may access the call via the toll-free dial-in number at 1-888-300-2035, or the toll dial-in number at 1-646-517-7437. The conference ID access code is 1058917.
All interested stakeholders are encouraged to access the simultaneous live webcast by visiting the investor relations page of the Owens & Minor website available at investors.owens-minor.com/events-and-presentations/. A replay of the webcast can be accessed following the presentation at the link provided above.
Safe Harbor
This release is intended to be disclosure through methods reasonably designed to provide broad, non-exclusionary distribution to the public in compliance with the SEC's Fair Disclosure Regulation. This release contains certain ''forward-looking'' statements made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, the statements in this release regarding our future prospects and performance, including our expectations with respect to our 2023 financial performance, our Operating Model Realignment Program and other cost-saving initiatives, future indebtedness and growth, industry trends, as well as statements related to our expectations regarding the performance of its business, including the results of our Operating Model Realignment Program and our ability to address macro and market conditions. Forward-looking statements involve known and unknown risks and uncertainties that may cause our actual results in future periods to differ materially from those projected or contemplated in the forward-looking statements. Investors should refer to Owens & Minor’s Annual Report on Form 10-K for the year ended December 31, 2022, filed with the SEC including the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and subsequent quarterly reports on Form 10-Q and current reports on Form 8-K filed with or furnished to the SEC, for a discussion of certain known risk factors that could cause the Company’s actual results to differ materially from its current estimates. These filings are available at www.owens-minor.com. Given these risks and uncertainties, Owens & Minor can give no assurance that any forward-looking statements will, in fact, transpire and, therefore, cautions investors not to place undue reliance on them. Owens & Minor specifically disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future developments or otherwise.
About Owens & Minor
Owens & Minor, Inc. (NYSE: OMI) is a Fortune 500 global healthcare solutions company integrating product manufacturing and delivery, home health supply and perioperative services to support care through the hospital and into the home. Owens & Minor drives visibility, control and efficiency for patients, providers and healthcare professionals across the supply chain with proprietary technology and solutions, an extensive product portfolio, an Americas-based manufacturing footprint for personal protective equipment and surgical products, as well as a robust portfolio of products and services for patients managing chronic and acute conditions in the home setting. Operating continuously since 1882 from its headquarters in Richmond, Va., Owens & Minor is a 140-year-old company powered by more than 20,000 global teammates. Learn more at https://www.owens-minor.com, follow @Owens_Minor on Twitter and connect on LinkedIn at www.linkedin.com/company/owens-&-minor.
Owens & Minor, Inc. | ||||||||
Consolidated Statements of Operations (unaudited) | ||||||||
(dollars in thousands, except per share data) | ||||||||
| Three Months Ended | |||||||
| 2023 |
| 2022 | |||||
Net revenue | $ | 2,591,742 |
|
| $ | 2,497,401 |
| |
Cost of goods sold |
| 2,053,244 |
|
|
| 1,984,122 |
| |
Gross margin |
| 538,498 |
|
|
| 513,279 |
| |
Distribution, selling and administrative expenses |
| 452,583 |
|
|
| 430,957 |
| |
Acquisition-related charges and intangible amortization |
| 30,217 |
|
|
| 21,217 |
| |
Exit and realignment charges |
| 30,180 |
|
|
| 1,983 |
| |
Other operating expense (income), net |
| 1,677 |
|
|
| (1,125 | ) | |
Operating income |
| 23,841 |
|
|
| 60,247 |
| |
Interest expense, net |
| 38,127 |
|
|
| 39,869 |
| |
Other (income) expense, net |
| (3,302 | ) |
|
| 783 |
| |
(Loss) income before income taxes |
| (10,984 | ) |
|
| 19,595 |
| |
Income tax (benefit) provision |
| (4,558 | ) |
|
| 7,098 |
| |
Net (loss) income | $ | (6,426 | ) |
| $ | 12,497 |
| |
|
|
|
| |||||
Net (loss) income per common share: |
|
|
| |||||
Basic | $ | (0.08 | ) |
| $ | 0.17 |
| |
Diluted | $ | (0.08 | ) |
| $ | 0.16 |
|
Owens & Minor, Inc. | ||||||||
Consolidated Statements of Operations (unaudited) | ||||||||
(dollars in thousands, except per share data) | ||||||||
| Nine Months Ended September 30, | |||||||
| 2023 |
| 2022 | |||||
Net revenue | $ | 7,677,817 |
|
| $ | 7,404,368 |
| |
Cost of goods sold |
| 6,122,579 |
|
|
| 5,985,136 |
| |
Gross margin |
| 1,555,238 |
|
|
| 1,419,232 |
| |
Distribution, selling and administrative expenses |
| 1,356,334 |
|
|
| 1,122,353 |
| |
Acquisition-related charges and intangible amortization |
| 74,609 |
|
|
| 100,628 |
| |
Exit and realignment charges |
| 74,817 |
|
|
| 4,879 |
| |
Other operating expense (income), net |
| 4,991 |
|
|
| (5,020 | ) | |
Operating income |
| 44,487 |
|
|
| 196,392 |
| |
Interest expense, net |
| 121,053 |
|
|
| 87,727 |
| |
Other (income) expense, net |
| (843 | ) |
|
| 2,347 |
| |
(Loss) income before income taxes |
| (75,723 | ) |
|
| 106,318 |
| |
Income tax (benefit) provision |
| (16,638 | ) |
|
| 25,937 |
| |
Net (loss) income | $ | (59,085 | ) |
| $ | 80,381 |
| |
|
|
|
| |||||
Net (loss) income per common share: |
|
|
| |||||
Basic | $ | (0.78 | ) |
| $ | 1.08 |
| |
Diluted | $ | (0.78 | ) |
| $ | 1.05 |
|
Owens & Minor, Inc. | ||||||
Condensed Consolidated Balance Sheets (unaudited) | ||||||
(dollars in thousands) | ||||||
| September 30, |
| December 31, | |||
| 2023 |
| 2022 | |||
Assets |
|
|
| |||
Current assets |
|
|
| |||
Cash and cash equivalents | $ | 215,191 |
| $ | 69,467 | |
Accounts receivable, net of allowances of $9,196 and $9,063 |
| 682,682 |
|
| 763,497 | |
Merchandise inventories |
| 1,084,350 |
|
| 1,333,585 | |
Other current assets |
| 148,046 |
|
| 128,636 | |
Total current assets |
| 2,130,269 |
|
| 2,295,185 | |
Property and equipment, net of accumulated depreciation of $532,399 and $450,286 |
| 540,419 |
|
| 578,269 | |
Operating lease assets |
| 300,264 |
|
| 280,665 | |
Goodwill |
| 1,635,010 |
|
| 1,636,705 | |
Intangible assets, net |
| 381,557 |
|
| 445,042 | |
Other assets, net |
| 136,544 |
|
| 150,417 | |
Total assets | $ | 5,124,063 |
| $ | 5,386,283 | |
Liabilities and equity |
|
|
| |||
Current liabilities |
|
|
| |||
Accounts payable | $ | 1,182,408 |
| $ | 1,147,414 | |
Accrued payroll and related liabilities |
| 106,194 |
|
| 93,296 | |
Other current liabilities |
| 443,579 |
|
| 325,756 | |
Total current liabilities |
| 1,732,181 |
|
| 1,566,466 | |
Long-term debt, excluding current portion |
| 2,113,602 |
|
| 2,482,968 | |
Operating lease liabilities, excluding current portion of $85,149 and $76,805 |
| 225,208 |
|
| 215,469 | |
Deferred income taxes |
| 45,616 |
|
| 60,833 | |
Other liabilities |
| 120,596 |
|
| 114,943 | |
Total liabilities |
| 4,237,203 |
|
| 4,440,679 | |
Total equity |
| 886,860 |
|
| 945,604 | |
Total liabilities and equity | $ | 5,124,063 |
| $ | 5,386,283 |
Owens & Minor, Inc. | ||||||||
Consolidated Statements of Cash Flows (unaudited) | ||||||||
(dollars in thousands) | ||||||||
| Three Months Ended | |||||||
| 2023 |
| 2022 | |||||
Operating activities: |
|
|
| |||||
Net (loss) income | $ | (6,426 | ) |
| $ | 12,497 |
| |
Adjustments to reconcile net (loss) income to cash provided by operating activities: |
|
|
| |||||
Depreciation and amortization |
| 73,652 |
|
|
| 58,151 |
| |
Share-based compensation expense |
| 5,742 |
|
|
| 4,555 |
| |
Provision for losses on accounts receivable |
| 413 |
|
|
| 777 |
| |
Gain on extinguishment of debt |
| (5,222 | ) |
|
| — |
| |
Deferred income tax (benefit) provision |
| (9,557 | ) |
|
| 1,390 |
| |
Changes in operating lease right-of-use assets and lease liabilities |
| 1,560 |
|
|
| 316 |
| |
Gain on sale and dispositions of property and equipment |
| (7,899 | ) |
|
| (17,228 | ) | |
Changes in operating assets and liabilities, net of acquisitions: |
|
|
| |||||
Accounts receivable |
| (13,006 | ) |
|
| (8,858 | ) | |
Merchandise inventories |
| 81,406 |
|
|
| 17,615 |
| |
Accounts payable |
| (5,821 | ) |
|
| 18,075 |
| |
Net change in other assets and liabilities |
| 39,913 |
|
|
| (21,478 | ) | |
Other, net |
| 2,680 |
|
|
| 2,709 |
| |
Cash provided by operating activities |
| 157,435 |
|
|
| 68,521 |
| |
Investing activities: |
|
|
| |||||
Additions to property and equipment |
| (47,728 | ) |
|
| (47,039 | ) | |
Additions to computer software |
| (2,860 | ) |
|
| (2,410 | ) | |
Proceeds from sale of property and equipment |
| 17,916 |
|
|
| 23,874 |
| |
Other, net |
| — |
|
|
| (831 | ) | |
Cash used for investing activities |
| (32,672 | ) |
|
| (26,406 | ) | |
Financing activities: |
|
|
| |||||
Borrowings under amended Receivables Financing Agreement |
| 127,800 |
|
|
| 349,900 |
| |
Repayments under amended Receivables Financing Agreement |
| (127,800 | ) |
|
| (367,900 | ) | |
Repayments of debt |
| (191,888 | ) |
|
| (1,500 | ) | |
Financing costs paid |
| — |
|
|
| (1,123 | ) | |
Other, net |
| 8,893 |
|
|
| 575 |
| |
Cash used for financing activities |
| (182,995 | ) |
|
| (20,048 | ) | |
Effect of exchange rate changes on cash, cash equivalents and restricted cash |
| (711 | ) |
|
| (1,888 | ) | |
Net (decrease) increase in cash, cash equivalents and restricted cash |
| (58,943 | ) |
|
| 20,179 |
| |
Cash, cash equivalents and restricted cash at beginning of period |
| 309,103 |
|
|
| 73,029 |
| |
Cash, cash equivalents and restricted cash at end of period(1) | $ | 250,160 |
|
| $ | 93,208 |
| |
Supplemental disclosure of cash flow information: |
|
|
| |||||
Income taxes paid, net | $ | 3,708 |
|
| $ | 7,786 |
| |
Interest paid | $ | 22,454 |
|
| $ | 29,472 |
| |
Noncash investing activity: |
|
|
| — |
| |||
Unpaid purchases of property and equipment and computer software at end of period | $ | 60,870 |
|
| $ | 63,158 |
|
(1) Restricted cash, as of September 30, 2023 and June 30, 2023 was $35.0 million and $22.8 million, includes amounts held in an escrow account as required by the Centers for Medicare & Medicaid Services (CMS) in conjunction with the Bundled Payments for Care Improvement (BPCI) initiatives related to wind-down costs of Fusion5. Restricted cash as of September 30, 2023 and June 30, 2023 also includes $18.6 million and $6.4 million of restricted cash deposits received under the Master Receivables Purchase Agreement to be remitted to a third-party financial institution. |
Owens & Minor, Inc. | ||||||||
Consolidated Statements of Cash Flows (unaudited) | ||||||||
(dollars in thousands) | ||||||||
| Nine Months Ended September 30, | |||||||
| 2023 |
| 2022 | |||||
Operating activities: |
|
|
| |||||
Net (loss) income | $ | (59,085 | ) |
| $ | 80,381 |
| |
Adjustments to reconcile net (loss) income to cash provided by operating activities: |
|
|
| |||||
Depreciation and amortization |
| 216,640 |
|
|
| 155,438 |
| |
Share-based compensation expense |
| 17,417 |
|
|
| 15,765 |
| |
(Benefit) provision for losses on accounts receivable |
| (487 | ) |
|
| 5,289 |
| |
Gain on extinguishment of debt |
| (4,379 | ) |
|
| — |
| |
Deferred income tax (benefit) provision |
| (16,315 | ) |
|
| 2,991 |
| |
Changes in operating lease right-of-use assets and lease liabilities |
| (1,517 | ) |
|
| 922 |
| |
Gain on sale and dispositions of property and equipment |
| (26,462 | ) |
|
| (17,002 | ) | |
Changes in operating assets and liabilities, net of acquisitions: |
|
|
| |||||
Accounts receivable |
| 77,197 |
|
|
| 7,417 |
| |
Merchandise inventories |
| 247,057 |
|
|
| (6,823 | ) | |
Accounts payable |
| 46,338 |
|
|
| 30,424 |
| |
Net change in other assets and liabilities |
| 122,867 |
|
|
| (45,423 | ) | |
Other, net |
| 9,674 |
|
|
| 8,666 |
| |
Cash provided by operating activities |
| 628,945 |
|
|
| 238,045 |
| |
Investing activities: |
|
|
| |||||
Acquisition, net of cash acquired |
| — |
|
|
| (1,684,607 | ) | |
Additions to property and equipment |
| (140,478 | ) |
|
| (109,275 | ) | |
Additions to computer software |
| (11,089 | ) |
|
| (5,873 | ) | |
Proceeds from sale of property and equipment |
| 53,645 |
|
|
| 29,720 |
| |
Other, net |
| (418 | ) |
|
| (1,670 | ) | |
Cash used for investing activities |
| (98,340 | ) |
|
| (1,771,705 | ) | |
Financing activities: |
|
|
| |||||
Borrowings under amended Receivables Financing Agreement |
| 476,000 |
|
|
| 697,700 |
| |
Repayments under amended Receivables Financing Agreement |
| (572,000 | ) |
|
| (770,700 | ) | |
Repayments of debt |
| (270,189 | ) |
|
| (3,000 | ) | |
Proceeds from issuance of debt |
| — |
|
|
| 1,691,000 |
| |
Borrowings under revolving credit facility, net and Receivables Financing Agreement |
| — |
|
|
| 30,000 |
| |
Financing costs paid |
| — |
|
|
| (42,602 | ) | |
Other, net |
| 74 |
|
|
| (41,813 | ) | |
Cash (used for) provided by financing activities |
| (366,115 | ) |
|
| 1,560,585 |
| |
Effect of exchange rate changes on cash, cash equivalents and restricted cash |
| (515 | ) |
|
| (5,752 | ) | |
Net increase in cash, cash equivalents and restricted cash |
| 163,975 |
|
|
| 21,173 |
| |
Cash, cash equivalents and restricted cash at beginning of period |
| 86,185 |
|
|
| 72,035 |
| |
Cash, cash equivalents and restricted cash at end of period(1) | $ | 250,160 |
|
| $ | 93,208 |
| |
Supplemental disclosure of cash flow information: |
|
|
| |||||
Income taxes (received) paid, net | $ | (6,798 | ) |
| $ | 33,568 |
| |
Interest paid | $ | 101,079 |
|
| $ | 61,889 |
| |
Noncash investing activity: |
|
|
| |||||
Unpaid purchases of property and equipment and computer software at end of period | $ | 60,870 |
|
| $ | 63,158 |
|
(1) Restricted cash, as of September 30, 2023 and December 31, 2022 was $35.0 million and $16.7 million, includes amounts held in an escrow account as required by the CMS in conjunction with the BPCI initiatives related to wind-down costs of Fusion5. Restricted cash as of September 30, 2023 also includes $18.6 million of restricted cash deposits received under the Master Receivables Purchase Agreement to be remitted to a third-party financial institution. |
Owens & Minor, Inc. | ||||||||||||||
Summary Segment Information (unaudited) | ||||||||||||||
(dollars in thousands) | ||||||||||||||
| Three Months Ended September 30, | |||||||||||||
| 2023 |
| 2022 | |||||||||||
|
|
| % of |
|
|
| % of | |||||||
|
|
| consolidated |
|
|
| consolidated | |||||||
| Amount |
| net revenue |
| Amount |
| net revenue | |||||||
Net revenue: |
|
|
|
|
|
|
| |||||||
Products & Healthcare Services | $ | 1,943,467 |
|
| 74.99 | % |
| $ | 1,903,356 |
|
| 76.21 | % | |
Patient Direct |
| 648,275 |
|
| 25.01 | % |
|
| 594,045 |
|
| 23.79 | % | |
Consolidated net revenue | $ | 2,591,742 |
|
| 100.00 | % |
| $ | 2,497,401 |
|
| 100.00 | % | |
|
|
|
|
|
|
|
| |||||||
|
|
| % of segment |
|
|
| % of segment | |||||||
Operating income: |
|
| net revenue |
|
|
| net revenue | |||||||
Products & Healthcare Services | $ | 19,803 |
|
| 1.02 | % |
| $ | 23,781 |
|
| 1.25 | % | |
Patient Direct |
| 64,435 |
|
| 9.94 | % |
|
| 59,666 |
|
| 10.04 | % | |
Acquisition-related charges and intangible amortization |
| (30,217 | ) |
|
|
|
| (21,217 | ) |
|
| |||
Exit and realignment charges |
| (30,180 | ) |
|
|
|
| (1,983 | ) |
|
| |||
Consolidated operating income | $ | 23,841 |
|
| 0.92 | % |
| $ | 60,247 |
|
| 2.41 | % | |
|
|
|
|
|
|
|
| |||||||
Depreciation and amortization: |
|
|
|
|
|
|
| |||||||
Products & Healthcare Services | $ | 20,021 |
|
|
|
| $ | 19,121 |
|
|
| |||
Patient Direct |
| 53,631 |
|
|
|
|
| 39,030 |
|
|
| |||
Consolidated depreciation and amortization | $ | 73,652 |
|
|
|
| $ | 58,151 |
|
|
| |||
|
|
|
|
|
|
|
| |||||||
Capital expenditures: |
|
|
|
|
|
|
| |||||||
Products & Healthcare Services | $ | 5,023 |
|
|
|
| $ | 9,743 |
|
|
| |||
Patient Direct |
| 45,565 |
|
|
|
|
| 39,706 |
|
|
| |||
Consolidated capital expenditures | $ | 50,588 |
|
|
|
| $ | 49,449 |
|
|
|
Owens & Minor, Inc. | ||||||||||||||
Summary Segment Information (unaudited) | ||||||||||||||
(dollars in thousands) | ||||||||||||||
| Nine Months Ended September 30, | |||||||||||||
| 2023 |
| 2022 | |||||||||||
|
|
| % of |
|
|
| % of | |||||||
|
|
| consolidated |
|
|
| consolidated | |||||||
| Amount |
| net revenue |
| Amount |
| net revenue | |||||||
Net revenue: |
|
|
|
|
|
|
| |||||||
Products & Healthcare Services | $ | 5,789,679 |
|
| 75.41 | % |
| $ | 5,964,784 |
|
| 80.56 | % | |
Patient Direct |
| 1,888,138 |
|
| 24.59 | % |
|
| 1,439,584 |
|
| 19.44 | % | |
Consolidated net revenue | $ | 7,677,817 |
|
| 100.00 | % |
| $ | 7,404,368 |
|
| 100.00 | % | |
|
|
|
|
|
|
|
| |||||||
|
|
| % of segment |
|
|
| % of segment | |||||||
Operating income: |
|
| net revenue |
|
|
| net revenue | |||||||
Products & Healthcare Services | $ | 24,564 |
|
| 0.42 | % |
| $ | 174,108 |
|
| 2.92 | % | |
Patient Direct |
| 169,349 |
|
| 8.97 | % |
|
| 127,791 |
|
| 8.88 | % | |
Acquisition-related charges and intangible amortization |
| (74,609 | ) |
|
|
|
| (100,628 | ) |
|
| |||
Exit and realignment charges |
| (74,817 | ) |
|
|
|
| (4,879 | ) |
|
| |||
Consolidated operating income | $ | 44,487 |
|
| 0.58 | % |
| $ | 196,392 |
|
| 2.65 | % | |
|
|
|
|
|
|
|
| |||||||
Depreciation and amortization: |
|
|
|
|
|
|
| |||||||
Products & Healthcare Services | $ | 57,360 |
|
|
|
| $ | 57,325 |
|
|
| |||
Patient Direct |
| 159,280 |
|
|
|
|
| 98,113 |
|
|
| |||
Consolidated depreciation and amortization | $ | 216,640 |
|
|
|
| $ | 155,438 |
|
|
| |||
|
|
|
|
|
|
|
| |||||||
Capital expenditures: |
|
|
|
|
|
|
| |||||||
Products & Healthcare Services | $ | 17,957 |
|
|
|
| $ | 38,804 |
|
|
| |||
Patient Direct |
| 133,610 |
|
|
|
|
| 76,344 |
|
|
| |||
Consolidated capital expenditures | $ | 151,567 |
|
|
|
| $ | 115,148 |
|
|
|
Owens & Minor, Inc. | ||||||||||||||
Net (Loss) Income Per Common Share (unaudited) | ||||||||||||||
(dollars in thousands, except per share data) | ||||||||||||||
| Three Months Ended |
| Nine Months Ended | |||||||||||
| 2023 |
| 2022 |
| 2023 |
| 2022 | |||||||
Net (loss) income | $ | (6,426 | ) |
| $ | 12,497 |
| $ | (59,085 | ) |
| $ | 80,381 | |
|
|
|
|
|
|
|
| |||||||
Weighted average shares outstanding - basic |
| 76,203 |
|
|
| 74,905 |
|
| 75,691 |
|
|
| 74,376 | |
Dilutive shares |
| — |
|
|
| 1,510 |
|
| — |
|
|
| 1,835 | |
Weighted average shares outstanding - diluted |
| 76,203 |
|
|
| 76,415 |
|
| 75,691 |
|
|
| 76,211 | |
|
|
|
|
|
|
|
| |||||||
Net (loss) income per common share: |
|
|
|
|
|
|
| |||||||
Basic | $ | (0.08 | ) |
| $ | 0.17 |
| $ | (0.78 | ) |
| $ | 1.08 | |
Diluted | $ | (0.08 | ) |
| $ | 0.16 |
| $ | (0.78 | ) |
| $ | 1.05 |
Share-based awards for the three and nine months ended September 30, 2023 of approximately 1.5 million and 1.6 million shares were excluded from the calculation of net loss per diluted common share as the effect would be anti-dilutive. |
Owens & Minor, Inc. | ||||||||||||||||
GAAP/Non-GAAP Reconciliations (unaudited) | ||||||||||||||||
(dollars in thousands, except per share data) | ||||||||||||||||
The following table provides a reconciliation of reported operating income, net (loss) income and net (loss) income per share to non-GAAP measures used by management. | ||||||||||||||||
|
| Three Months Ended |
| Nine Months Ended | ||||||||||||
|
| 2023 |
| 2022 |
| 2023 |
| 2022 | ||||||||
Operating income, as reported (GAAP) |
| $ | 23,841 |
|
| $ | 60,247 |
|
| $ | 44,487 |
|
| $ | 196,392 |
|
Acquisition-related charges and intangible amortization (1) |
|
| 30,217 |
|
|
| 21,217 |
|
|
| 74,609 |
|
|
| 100,628 |
|
Exit and realignment charges (2) |
|
| 30,180 |
|
|
| 1,983 |
|
|
| 74,817 |
|
|
| 4,879 |
|
Operating income, adjusted (non-GAAP) (Adjusted Operating Income) |
| $ | 84,238 |
|
| $ | 83,447 |
|
| $ | 193,913 |
|
| $ | 301,899 |
|
Operating income as a percent of net revenue (GAAP) |
|
| 0.92 | % |
|
| 2.41 | % |
|
| 0.58 | % |
|
| 2.65 | % |
Adjusted operating income as a percent of net revenue (non-GAAP) |
|
| 3.25 | % |
|
| 3.34 | % |
|
| 2.53 | % |
|
| 4.08 | % |
|
|
|
|
|
|
|
|
| ||||||||
Net (loss) income, as reported (GAAP) |
| $ | (6,426 | ) |
| $ | 12,497 |
|
| $ | (59,085 | ) |
| $ | 80,381 |
|
Pre-tax adjustments: |
|
|
|
|
|
|
|
| ||||||||
Acquisition-related charges and intangible amortization (1) |
|
| 30,217 |
|
|
| 21,217 |
|
|
| 74,609 |
|
|
| 100,628 |
|
Exit and realignment charges (2) |
|
| 30,180 |
|
|
| 1,983 |
|
|
| 74,817 |
|
|
| 4,879 |
|
Other (3) |
|
| (4,657 | ) |
|
| 525 |
|
|
| (2,685 | ) |
|
| 1,574 |
|
Income tax benefit on pre-tax adjustments (4) |
|
| (15,180 | ) |
|
| (4,776 | ) |
|
| (35,711 | ) |
|
| (25,002 | ) |
Net income, adjusted (non-GAAP) (Adjusted Net Income) |
| $ | 34,134 |
|
| $ | 31,446 |
|
| $ | 51,945 |
|
| $ | 162,460 |
|
|
|
|
|
|
|
|
|
| ||||||||
Net (loss) income per common share, as reported (GAAP) |
| $ | (0.08 | ) |
| $ | 0.16 |
|
| $ | (0.78 | ) |
| $ | 1.05 |
|
After-tax adjustments: |
|
|
|
|
|
|
|
| ||||||||
Acquisition-related charges and intangible amortization (1) |
|
| 0.28 |
|
|
| 0.22 |
|
|
| 0.74 |
|
|
| 1.01 |
|
Exit and realignment charges (2) |
|
| 0.28 |
|
|
| 0.02 |
|
|
| 0.74 |
|
|
| 0.05 |
|
Other (3) |
|
| (0.04 | ) |
|
| 0.01 |
|
|
| (0.03 | ) |
|
| 0.02 |
|
Net income per common share, adjusted (non-GAAP) (Adjusted EPS) |
| $ | 0.44 |
|
| $ | 0.41 |
|
| $ | 0.67 |
|
| $ | 2.13 |
|
Owens & Minor, Inc. | ||||||||||||||||
GAAP/Non-GAAP Reconciliations (unaudited), continued | ||||||||||||||||
(dollars in thousands) | ||||||||||||||||
The following tables provide reconciliations of net (loss) income and total debt to non-GAAP measures used by management. | ||||||||||||||||
|
| Three Months Ended |
| Nine Months Ended | ||||||||||||
|
| 2023 |
| 2022 |
| 2023 |
| 2022 | ||||||||
Net (loss) income, as reported (GAAP) |
| $ | (6,426 | ) |
| $ | 12,497 |
|
| $ | (59,085 | ) |
| $ | 80,381 |
|
Income tax (benefit) provision |
|
| (4,558 | ) |
|
| 7,098 |
|
|
| (16,638 | ) |
|
| 25,937 |
|
Interest expense, net |
|
| 38,127 |
|
|
| 39,869 |
|
|
| 121,053 |
|
|
| 87,727 |
|
Acquisition-related charges and intangible amortization (1) |
|
| 30,217 |
|
|
| 21,217 |
|
|
| 74,609 |
|
|
| 100,628 |
|
Exit and realignment charges (2) |
|
| 30,180 |
|
|
| 1,983 |
|
|
| 74,817 |
|
|
| 4,879 |
|
Other depreciation and amortization (5) |
|
| 50,909 |
|
|
| 43,849 |
|
|
| 151,635 |
|
|
| 99,979 |
|
Stock compensation (6) |
|
| 4,616 |
|
|
| 5,374 |
|
|
| 15,761 |
|
|
| 15,593 |
|
LIFO credits (7) |
|
| (3,660 | ) |
|
| (4,957 | ) |
|
| (3,253 | ) |
|
| (3,331 | ) |
Other (3) |
|
| (4,657 | ) |
|
| 525 |
|
|
| (2,685 | ) |
|
| 1,574 |
|
Adjusted EBITDA (non-GAAP) |
| $ | 134,748 |
|
| $ | 127,455 |
|
| $ | 356,214 |
|
| $ | 413,367 |
|
|
| September 30, | ||
|
| 2023 | ||
Total debt, as reported (GAAP) |
| $ | 2,146,037 |
|
Cash and cash equivalents |
|
| (215,191 | ) |
Net debt (non-GAAP) |
| $ | 1,930,846 |
|
Owens & Minor, Inc.
GAAP/Non-GAAP Reconciliations (unaudited), continued
The following items have been excluded in our non-GAAP financial measures:
(1) Acquisition-related charges and intangible amortization includes acquisition-related charges of $9.4 million and $6.9 million for the three months ended September 30, 2023 and 2022 and $11.9 million and $45.2 million for the nine months ended September 30, 2023 and 2022, as well as amortization of intangible assets established during acquisition method of accounting for business combinations. Acquisition-related charges consist primarily of one-time costs related to the Apria Acquisition, including transaction costs necessary to consummate the acquisition, which consisted of investment banking advisory fees and legal fees, director and officer tail insurance expense, severance and retention bonuses, and professional fees. These amounts are highly dependent on the size and frequency of acquisitions and are being excluded to allow for a more consistent comparison with forecasted, current and historical results.
(2) During the three and nine months ended September 30, 2023 exit and realignment charges were $30.2 million and $74.8 million. These charges primarily related to our (1) Operating Model Realignment Program of $24.5 million and $63.9 million, including professional fees, severance and other costs to streamline functions and processes, (2) IT restructuring charges such as converting to common IT systems of $3.3 million and $6.7 million and, (3) other costs associated with strategic initiatives of $2.4 million and $4.1 million for the three and nine months ended September 30, 2023. Exit and realignment charges were $2.0 million and $4.9 million for the three and nine months ended September 30, 2022 and consisted primarily of severance and other charges associated with the reorganization of our segments. These costs are not normal recurring, cash operating expenses necessary for the Company to operate its business on an ongoing basis.
(3) For the three and nine months ended September 30, 2023 other includes gain on extinguishment of debt of $5.2 million and $4.4 million associated with the early retirement of indebtedness of $195 million and $268 million. Additionally, for the three and nine months ended September 30, 2023 and 2022, other includes interest costs and net actuarial losses related to our frozen noncontributory, unfunded retirement plan for certain retirees in the United States (U.S.).
(4) These charges have been tax effected by determining the income tax rate depending on the amount of charges incurred in different tax jurisdictions and the deductibility of those charges for income tax purposes.
(5) Other depreciation and amortization relates to property and equipment and capitalized computer software, excluding such amounts captured within exit and realignment charges or acquisition-related charges.
(6) Stock compensation includes share-based compensation expense related to our share-based compensation plans, excluding such amounts captured within exit and realignment charges or acquisition-related charges.
(7) LIFO credits includes non-cash adjustments to merchandise inventories valued at the lower of cost or market, with the approximate cost determined by the last-in, first-out (LIFO) method for distribution inventories in the U.S. within our Products & Healthcare Services segment.
Use of Non-GAAP Measures
This earnings release contains financial measures that are not calculated in accordance with U.S. generally accepted accounting principles (GAAP). In general, the measures exclude items and charges that (i) management does not believe reflect Owens & Minor, Inc.'s (the Company) core business and relate more to strategic, multi-year corporate activities; or (ii) relate to activities or actions that may have occurred over multiple or in prior periods without predictable trends. Management uses these non-GAAP financial measures internally to evaluate the Company's performance, evaluate the balance sheet, engage in financial and operational planning and determine incentive compensation.
Management provides these non-GAAP financial measures to investors as supplemental metrics to assist readers in assessing the effects of items and events on its financial and operating results and in comparing the Company's performance to that of its competitors. However, the non-GAAP financial measures used by the Company may be calculated differently from, and therefore may not be comparable to, similarly titled measures used by other companies.
The non-GAAP financial measures disclosed by the Company should not be considered substitutes for, or superior to, financial measures calculated in accordance with GAAP, and the financial results calculated in accordance with GAAP and reconciliations to those financial statements set forth above should be carefully evaluated.
Last Trade: | US$12.55 |
Daily Change: | -0.01 -0.08 |
Daily Volume: | 126,667 |
Market Cap: | US$967.730M |
December 02, 2024 November 04, 2024 September 10, 2024 September 09, 2024 August 02, 2024 |
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORECue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB